Ditropan XL oxybutynin: Phase III; marketed

Data from a 226-patient Phase III trial showed an 81 percent reduction in urinary incontinence episodes (from 18.6 per week to 2.9 per week) with Ditropan XL versus a 75 percent reduction with an imme...